提示: 手机请竖屏浏览!

慢性肝病患者的饮酒
Alcohol Use in Patients with Chronic Liver Disease


Daniel Fuster ... 其他 • 2018.09.27
相关阅读
• 新版酒精性肝病管理指南

在全世界,饮酒是导致死亡以及疾病和损伤负担的第七大危险因素1。在男性的年龄标准化死亡中有6.8%是由饮酒导致,在女性中有2.2%是由饮酒导致,饮酒对年轻人群体的影响尤大。在高收入和中等收入国家,与饮酒有关的总成本占国民生产总值的1%以上,饮酒的社会危害(例如暴力和交通事故)所带来的成本远超过单纯健康方面的成本2。简而言之,除了烟草,酒精比其他任何成瘾物质造成的疾病负担都要高3。在本综述中,我们讨论了饮酒对各种肝病的影响,以及对慢性肝病患者饮酒的评估和治疗。





作者信息

Daniel Fuster, M.D., Ph.D., and Jeffrey H. Samet, M.D., M.P.H.
From the Internal Medicine Service, Addiction Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain (D.F.); and the Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, the Grayken Center for Addiction, Boston Medical Center, and the Department of Community Health Sciences, Boston University School of Public Health — all in Boston ( J.H.S.). Address reprint requests to Dr. Samet at Boston University Schools of Medicine and Public Health, 801 Massachusetts Ave., 2nd Fl., Boston, MA 02118, or at jsamet@bu.edu.

 

参考文献

1. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018 August 23 (Epub ahead of print).

2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223-2233.

3. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-1210.

4. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399-420.

5. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013;59:160-168.

6. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev 2010;29:437-445.

7. Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 2016;169:101-109.

8. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010;51:307-328.

9. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758-2769.

10. Lieber CS, Jones DP, Decarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965;44:1009-1021.

11. Corrao G, Arico S, Carle F, et al. A case-control study on alcohol consumption and the risk of chronic liver disease. Rev Epidemiol Sante Publique 1991;39:333-343.

12. Hatton J, Burton A, Nash H, Munn E, Burgoyne L, Sheron N. Drinking patterns, dependency and life-time drinking history in alcohol-related liver disease. Addiction 2009;104:587-592.

13. Nielsen JK, Olafsson S, Bergmann OM, et al. Lifetime drinking history in patients with alcoholic liver disease and patients with alcohol use disorder without liver disease. Scand J Gastroenterol 2017;52:762-767.

14. Askgaard G, Grønbæk M, Kjær MS, Tjønneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 2015;62:1061-1067.

15. Naimi TS, Brewer RD, Mokdad A, Denny C, Serdula MK, Marks JS. Binge drinking among US adults. JAMA 2003;289:70-75.

16. Ventura-Cots M, Watts AE, Bataller R. Binge drinking as a risk factor for advanced alcoholic liver disease. Liver Int 2017;37:1281-1283.

17. Åberg F, Helenius-Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: a population-based cohort study. Liver Int 2017;37:1373-1381.

18. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997;41:845-850.

19. Tsukamoto H, Machida K, Dynnyk A, Mkrtchyan H. “Second hit” models of alcoholic liver disease. Semin Liver Dis 2009;29:178-187.

20. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015;12:231-242.

21. Lieber CS. Metabolism of alcohol. Clin Liver Dis 2005;9:1-35.

22. Purohit V, Bode JC, Bode C, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008;42:349-361.

23. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015;148:30-36.

24. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009;50:1258-1266.

25. Stoller EP, Hund AJ, Webster NJ, et al. Alcohol consumption within the context of hepatitis C: a qualitative study of non-problematic drinkers. Alcohol Alcohol 2006;41:546-552.

26. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.

27. Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol 2016;8:1295-1308.

28. Fishbein DA, Lo Y, Netski D, Thomas DL, Klein RS. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 2006;41:471-476.

29. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-1159.

30. Tsui JI, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006;44:262-266.

31. Fuster D, Cheng DM, Quinn EK, et al. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction 2014;109:62-70.

32. Fuster D, Sanvisens A, Bolao F, et al. Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. J Viral Hepat 2015;22:18-24.

33. Alavi M, Janjua NZ, Chong M, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. J Hepatol 2018;68:393-401.

34. Schwarzinger M, Baillot S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: a nationwide retrospective cohort study. J Hepatol 2017;67:454-461.

35. Larkin J, Clayton MM, Liu J, Feitelson MA. Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice. Hepatology 2001;34:792-797.

36. Lin CW, Lin CC, Mo LR, et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 2013;58:730-735.

37. Yamanaka T, Shiraki K, Nakazaawa S, et al. Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis. Anticancer Res 2001;21:4B:2937-2940.

38. Ong A, Wong VW, Wong GL, Chan HL. The effect of caffeine and alcohol consumption on liver fibrosis — a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int 2011;31:1047-1053.

39. Hagström H. Alcohol consumption in concomitant liver disease: how much is too much? Curr Hepatol Rep 2017;16:152-157.

40. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-2072.

41. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005;3:1260-1268.

42. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.

43. Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 2017;65:2090-2099.

44. Åberg F, Helenius-Hietala J, Puukka P, Färkkilä M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018;67:2141-2149.

45. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122:281-289.

46. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol 2003;30:131-136.

47. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut 2017;66:541-553.

48. Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015;62:232-242.

49. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — II. Addiction 1993;88:791-804.

50. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998;158:1789-1795.

51. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med 2009;24:783-788.

52. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis — early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009;104:768-774.

53. Saitz R. Unhealthy alcohol use. N Engl J Med 2005;352:596-607.

54. Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol 2016;65:618-630.

55. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2017;8:CD008502-CD008502.

56. Friedmann PD. Alcohol use in adults. N Engl J Med 2013;368:365-373.

57. Tsui JI, Saitz R, Cheng DM, et al. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV. J Gen Intern Med 2007;22:822-825.

58. Khan A, Tansel A, White DL, et al. Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol 2016;14(2):191-202.e1.

59. Saitz R, Cheng DM, Winter M, et al. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA 2013;310:1156-1167.

60. Watkins KE, Ober AJ, Lamp K, et al. Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial. JAMA Intern Med 2017;177:1480-1488.

61. Friedmann PD, Saitz R, Samet JH. Management of adults recovering from alcohol or other drug problems: relapse prevention in primary care. JAMA 1998;279:1227-1231.

62. Gual A, He Y, Torup L, van den Brink W, Mann K. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013;23:1432-1442.

63. Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med 2017;130:124-134.

64. Krampe H, Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 2010;16:2076-2090.

65. Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011;35:1749-1758.

66. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999;20:427-435.

67. Antabuse (disulfiram). Silver Spring, MD: Food and Drug Administration (package insert) (https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm194601.pdf).

68. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;12:CD001867-CD001867.

69. Garbutt JC, Greenblatt AM, West SL, et al. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 2014;109:1274-1284.

70. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-828.

71. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 2008;359:715-721.

72. Revia (naltrexone). Silver Spring, MD: Food and Drug Administration (package insert) (https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf).

73. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-537.

74. Hammarberg A, Jayaram-Lindström N, Beck O, Franck J, Reid MS. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl) 2009;205:53-62.

75. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010;9:CD004332-CD004332.

76. Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 2015;12(12):e1001924-e1001924.

77. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370:1915-1922.

78. Beraha EM, Salemink E, Goudriaan AE, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 2016;26:1950-1959.

79. Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction 2017;112:1173-1183.

80. Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009;2:135-142.

81. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014;174:70-77.

82. Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 2013;7:277-286.

83. Lucey MR. Liver transplantation for alcoholic liver disease. Nat Rev Gastroenterol Hepatol 2014;11:300-307.

84. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790-1800.

85. Lee BP, Mehta N, Platt L, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology 2018;155(2):422-430.e1.

服务条款 | 隐私政策 | 联系我们